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Objective:	We	report	a	case	of	a	woman	with	hyperammonemic	
encephalopathy	following	glutamine	supplementation.
Design:	Case	report.
Interventions:	Plasma	amino	acid	analysis	 suggestive	of	 a	urea	
cycle	defect	and	 initiation	of	a	 treatment	with	 lactulose	and	 the	
two	ammonia	scavenger	drugs	sodium	benzoate	and	phenylac-
etate.	Together	with	a	restricted	protein	intake	ammonia	and	glu-
tamine	plasma	levels	decreased	with	subsequent	improvement	of	
the	neurological	status.
Measurements and Main Results:	Massive	catabolism	and	exog-
enous	glutamine	administration	may	have	contributed	to	hyper-
ammonemia	and	hyperglutaminemia	in	this	patient.
Conclusion:	This	case	adds	further	concerns	regarding	glutamine	
administration	to	critically	ill	patients	and	implies	the	importance	of	
monitoring	ammonia	and	glutamine	serum	levels	in	such	patients.	
(Crit Care Med	2015;	43:e458–e460)
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Glutamine is rapidly depleted in hypercatabolic conditions, and supplementation in critically ill patients has been advocated (1). But some inves-
tigators report an increased mortality among critically ill 
patients receiving glutamine in addition to enteral feed-
ing (2, 3). Its role in the pathogenesis of ammonia-induced 
encephalopathy has been widely recognized (4). We present 
the case of a patient with metabolic encephalopathy fol-
lowing glutamine supplementation whose mental status 
was more closely related to plasma levels of glutamine than 
ammonia.
CASE REPORT
A 52-year-old woman was transferred to our department 
because of cerebral edema. One year after pancreaticoduo-
denectomy due to suspected duodenal gastrinoma with 
secondary total pancreatectomy because of anastomosis 
leakage, adhesiolysis was performed because of mechani-
cal partial intestinal obstruction. The postoperative course 
was complicated by abdominal wound healing disorder 
requiring multiple surgical revisions of the laparotomy 
wound. After a more extended debridement, septic shock 
with coagulopathy developed and was followed by altered 
mental status and myoclonus. Brain CT showed dif-
fuse cerebral edema and blood tests a hyperammonemia 
(271 μmol/L; reference value, 11–48 μmol/L). The patient 
was then referred to our hospital for further diagnosis and 
treatment. Since the primary operations, the patient lost 
around 30 kg of her body weight. For the last 3 days prior 
to referral, enteral glutamine supplementation (30 g each 
day) had been given. The total daily nitrogen intake during 
these 3 days of glutamine supplementation was 13 g, 17 g, 
and 21 g, respectively.
At admission, the patient was comatose (Glasgow Coma 
Scale 3) with otherwise normal vital signs. Laboratory tests 
showed increased total and direct bilirubin (107 μmol/L and 
70.6 μmol/L, respectively; reference values, < 17 μmol/L and 
< 5 μmol/L, respectively) with otherwise irrelevant altera-
tion of liver and coagulation tests. Blood gas analysis: 
pH, 7.48; base excess, –3.8 mmol/L; lactate, 2.3 mmol/L. 
Urinary analysis was negative for ketones and orotac-
iduria. Doppler ultrasound confirmed normal liver per-
fusion. Brain MRI and electroencephalography suggested 
metabolic encephalopathy. To rule out a blind-loop syn-
drome, gastroscopy was performed. Upon finding of 
Enterobacter cloacae in jejunal biopsy, antibiotic therapy 
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with doxycycline was initiated. Plasma amino acid analysis 
showed a marked elevation of glutamine, alanine, aspara-
gine, lysine, proline, and glycine (Table 1) and low to nor-
mal levels of most essential amino acids. The massively 
increased glutamine, alanine, and asparagine pointed 
toward a urea cycle defect and therefore a protein restric-
tion and a treatment with lactulose and the two ammonia 
scavenger drugs sodium benzoate and phenylacetate was 
begun. The protein and nitrogen intake was stopped the 
first 2 days in our department and then a carefully moni-
tored protein intake was begun. The patient received 4 g of 
nitrogen on day 3 and 6 g of nitrogen on day 4 and day 5 in 
our ICU. Under these measures, ammonia and glutamine 
plasma levels decreased with consequent improvement of 
neurologic status. Enzymatic analysis of transjugular liver 
biopsy found a 50% reduction of carbamoylphosphate 
synthase (CPS) activity.
After increasing protein intake, a decreased level of con-
sciousness, hemiparesis, and nonconvulsive status epilepti-
cus occurred. This clinical deterioration was paralleled by a 
rebound increase in plasma glutamine (2,230 μmol/L), but 
not ammonia levels (22 μmol/L) (Fig. 1). Sodium benzo-
ate was again administered and protein intake restricted, 
with prompt decrease of glutamine levels and neurologic 
improvement.
Seven weeks later, the patient was discharged without rel-
evant neuropsychologic deficits.
DISCUSSION
Hyperammonemia is well known as a cause of encephalopa-
thy. Risk factors include hepatic dysfunction, enteral bacte-
rial overgrowth, and a variety of metabolic conditions, such 
as hereditary urea cycle defects, organic acidemias, carni-
tine deficiency, and fatty acid oxidation defects (5). Among 
iatrogenic causes, parenteral nutrition, intrahepatic porto-
systemic shunts, and adverse drug reactions are the most 
prominent.
In our patient, no obvious cause of the hyperammo-
nemia could be identified. Liver failure was excluded, 
even though there was some degree of liver dysfunction 
and cholestasis. The latter cannot, however, account for 
the observed biochemistry. Blind-loop syndrome seemed 
unlikely, as the rebound decline in vigilance occurred after 
successful bacterial eradication. A paraneoplastic phenom-
enon was deemed improbable, as postoperative histologic 
examination failed to demonstrate the suspected gastri-
noma. No drugs that have been associated with hyperam-
monemia could be identified. The patient did not have the 
biochemical signs or any risk factor for Reye syndrome, 
rare among adults.
The extent of glutamine, alanine, and asparagine eleva-
tion was suggestive of a urea cycle defect. On the other 
hand, normal citrulline and arginine as well as undetect-
able argininosuccinate and orotate in urine did not point 
to a specific defect. This profile is, however, compatible 
with CPS deficiency. The observed reduced CPS activity 
could point toward a mild or secondary CPS deficiency, but 
sequencing of the corresponding gene failed to reveal any 
mutation. Alternatively, CPS could have been down-regu-
lated after total pancreatectomy.
Deficiency of N-acetylglutamate synthase (NAGS), 
the obligate activator of CPS, is clinically and biochemi-
cally indistinguishable from the latter. Molecular analysis 
of NAGS gene did not show any mutation although mild 
defects cannot be excluded. Therefore, NAGS deficiency 
cannot be completely ruled out as some patients have been 
shown to have reduced hepatic enzyme activity despite fail-
ure to detect gene mutations (6).
Hyperammonemia was accompanied by a disproportion-
ately high increase in the ammonia-buffering amino acid 
glutamine. Interestingly, clinical deterioration was more 
TAblE 1. Patient Values of Different 
Amino Acids at Hospital Admission With 
Reference Range and z Score
Amino Acids
Patient Value 
(μmol/l)
Reference Range 
(μmol/l) z Score
Alanine 1,870 200–550 17.09
Arginine 142 25–125 2.68
Asparagine 482 30–90 28.13
Aspartic acid 45 3–15 12
Citrulline 46 < 60 1.07
Cystine 39 20–85 –0.83
Glutamic acid 100 10–120 1.27
Glutamine 7,142 300–900 43.61
Glycine 1,316 120–400 15.09
Histidine 397 60–120 20.47
Isoleucine 63 45–115 –0.97
Leucine 128 70–200 –0.22
Lysine 746 125–250 17.87
Methionine 23 10–40 –0.27
Ornithine 215 30–100 8.57
Phenylalanine 78 30–85 1.49
Proline 1,436 100–380 17.09
Serine 418 60–170 11.02
Taurine 74 35–250 –1.27
Threonine 341 65–220 5.12
Tryptophan 6 30–90 –3.6
Tyrosine 64 40–100 –0.4
Valine 166 150–350 –1.68
The	z	score	describes	the	number	of	sds	an	observation	is	above	or	below	
the	mean.
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closely related to rising plasma levels of glutamine than 
ammonia. Excess of glutamine accumulating in the brain 
leads to impairment of mitochondrial function in astrocytes 
and by this means mediates neurotoxicity (7). The precise 
mechanisms are still debated. Our patient received enteral 
glutamine supplementation as she was treated for abdomi-
nal sepsis in another hospital before referral. The combi-
nation of mild hepatic dysfunction, malnutrition, catabolic 
muscle wasting, and intra-abdominal infection has been 
reported to contribute to idiopathic hyperammonemia (8). 
Our patient had been subjected to total pancreatectomy. 
This condition could have caused a further hormonal- 
metabolic imbalance (aglucagonemia and consecutive 
 relative hypoinsulinism) which in turn may have led to inhi-
bition or down-regulation of urea cycle enzymes, increasing 
the risk of developing toxic glutamine levels. The reason 
for the striking and recurrent glutamine elevation remains 
obscure. In animals, repressed urea cycle enzyme  synthesis 
is seen following malnutrition (9), as are changes in hepatic 
glutamine synthetase activity, possibly representing an 
attempt to survive with hyperammonemia (10). Such a 
reactive alteration of glutamine metabolism, counteracting 
reduced CPS activity after a prolonged catabolic state, might 
have been present in our patient as she was severely mal-
nourished after a prolonged and complicated postoperative 
course accompanied by 
intestinal malabsorption 
after the primary operations. 
Under such circumstances, 
exogenous glutamine admin-
istration can cause metabolic 
decompensation.
In summary, catabo-
lism, reduced CPS activity, 
and exogenous glutamine 
administration could have 
contributed to hyperam-
monemia and hyperglu-
taminemia in this patient. 
This case adds further con-
cerns regarding glutamine 
administration to critically 
ill patients and implies the 
importance of monitor-
ing ammonia and gluta-
mine serum levels in such 
patients.
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Figure 1. Plasma glutamine and ammonia levels in correlation with the Glasgow Coma Scale (GCS) during the 
patient hospitalization. Reference ranges are indicated in square brackets.
